TSO3 Inc

TSO3 — Investor Presentation (April 2012)

49 slides from TSO3's investor presentation, April 2012

  1. Slide 1: Corporate presentation

    Corporate presentation Updated Q1 2012 (as of March 31) Creating the Improved Standard in Healthcare Sterile Reprocessing

  2. Slide 2: Company Overview

    Company Overview • Founded 1998 • Designed and manufactured a low temperature sterilizer for medical devices • IPO 2001 • TSX: TOS • 59M shares outstanding

  3. Slide 3: Key Events Under Initial Management

    Key Events Under Initial Management 2002 • Received HC Authorization for first generation sterilizer (125L) 2003 • Received FDA Clearance for first generation sterilizer (125L) 2006 • Received FDA Clearance for additional claims to include rigid lumened instruments (125L) 2008 • TSO3 total 38 placem

  4. Slide 4: Renewed Leadership

    Renewed Leadership • R.M. (Ric) Rumble, CEO – Joined October 2008 – More than 25 years experience within the North American and Global medical device industry, capital and consumables – Business Unit Manager, Sterility Assurance – 3M – President - MediVators Inc – VP & GM – Global Healthcare Sterili

  5. Slide 5: Recent Key Events

    Recent Key Events • Adopts new and aggressive strategic plan in order to increase utility of sterilizer • Freezes design of new generation (STERIZONE® 125L+) sterilizer offering increased compatibility and speed 2009 • Signs global channel partner agreement with 3M™ for new generation sterilizer (TS

  6. Slide 6: Our Vision: To Create the Improved Standard in Healthcare

    Our Vision… To Create the Improved Standard in Healthcare Sterile Reprocessing

  7. Slide 7: Opportunity

    Opportunity Medical Sterile Reprocessing of Reusable Instruments 7

  8. Slide 8: In business to win

    In business to win The Product/ Solution The Market The Channel

  9. Slide 9: Why low temperature sterilization?

    Why low temperature sterilization?

  10. Slide 10: Market Drivers

    Market Drivers 10

  11. Slide 11: Growing Population

    Growing Population 17% increase 7.9% increase 2010 2020 More people = more surgeries Annals of Surgery. 2003 August; 238(2): 170-177.

  12. Slide 12: Aging Population

    Aging Population 60 53% 50 increase 65 yrs + 40 45 to 64 % Increase 15 to 44 30 - 15 yrs 20 10 0 2001 2005 2010 2015 2020 65 yrs+ is the fastest growing segment Annals of Surgery. 2003 August; 238(2): 170-177.

  13. Slide 13: Impact of Age on Demand for Surgery

    Impact of Age on Demand for Surgery 88% of ophthalmology surgeries Number of 70% of cardiothoracic surgeries procedures (average) 65% of urology surgeries 60% of general surgeries Age 45 55 65 75 As we age, we require more OR time Annals of Surgery. 2003 August; 238(2): 170-177.

  14. Slide 14: Advancement in Medical Techniques

    Advancement in Medical Techniques From Traditional Open Surgery To Minimally Invasive Surgery (MIS) 14

  15. Slide 15: 30 million MIS Procedures

    MIS Procedures Increasingly used and finding new applications everyday Orthopaedic Neurosurgery Pulmonary medicine 30 million MIS Gynaecology surgeries in US/year Urology Gastrointestinal Cardiology 15 The National Institute of Health (NIH).

  16. Slide 16: MIS Devices are Complex & Delicate

    MIS Devices are Complex & Delicate $50k Colonoscope 16

  17. Slide 17: MIS Devices require low temperature sterilization

    MIS Devices require low temperature sterilization

  18. Slide 18: Sterilization Areas in Hospitals

    Sterilization Areas in Hospitals 2 OR 1 CS OR OR OR OR Central Sterilization (CS) Operating Room Department (OR) Low Temperature Sterilization OR OR OR OR Gas Liquid OR Reprocessing and Sterile Storage Steam Sterilization 3 GI Gastrointestinal Department (GI) Liquid 18

  19. Slide 19: Customers want Throughput

    Customers want THROUGHPUT TSO3 sterilizer conjoint study July 2009 - Allegheny Marketing Group.

  20. Slide 20: Available Sterilization Solutions

    Available Sterilization Solutions Ethylene Oxyde Hydrogen Peroxide Liquid Hyg. Per. + Ozone (EtO) (H2O2) Peracetic Acid (PAA) (H2O2/O3) Efficacious Fast Specific use in OR Fast High material Limited in Liquid = Not terminal Efficacious compatibility efficacy sterilization Long cycles Limited in Repl

  21. Slide 21: Our Technology Enables Throughput

    Our Technology Enables Throughput By combining: • Efficacy & Compatibility • High loading capacity • Speed 21

  22. Slide 22: Market Overview / Low Temperature Sterilization

    Market Overview / Low Temperature Sterilization • Capital equipment business Worldwide Installed Base – Low temperature gas sterilizers in hospitals: • ~26,000 installed worldwide • Life span ~ 12 years US • Replacement business: 2,000 units/year Canada Europe • Consummables business ROW – Estimated

  23. Slide 23: A Winning Channel Partner

    A Winning Channel Partner • Innovative • Customer respected • Leading competitor in space • Globally established

  24. Slide 24: 3M Global Reach

    3M Global Reach TaN Ka " ; - }

  25. Slide 25: Activities and Results

    Activities and Results 25

  26. Slide 26: Key Strategic Activities

    Key Strategic Activities • Regulatory • Commercial • Enhanced Portfolio 26

  27. Slide 27: Regulatory Status USA

    Regulatory Status USA • Changing regulatory environment / request to re-file through new process • Re-filed June 30, 2011 • Subsequent additional data requested by Agency - filed April 20, 2012 Active file in progress - 11 months through the process 27

  28. Slide 28: What is moving through the US Regulatory Process from TSO3?

    What is moving through the US Regulatory Process from TSO3? Biological Indicator (BI) Process Indicator (CI) Test Pack Sterile Efficacy Validation Sterilizer 28

  29. Slide 29: General Nature of Questions

    General Nature of Questions Cycle 1 Monitoring Methods Cycle 2 Cycle 3 Demonstrating that same indicators effectively monitor cycles with different configurations 29

  30. Slide 30: Commercial launch 3M / TSO3

    Commercial launch 3M / TSO3 • Initiated phased global roll-out June 2011, based on regulatory clearances: – Health Canada clearance - Obtained – CE Mark for European Union - Obtained • 2011: – Product introduced in 11 countries second-half of the year (including APAC Region) (planned 15) – Executed

  31. Slide 31: 3M Product Positioning

    3M Product Positioning • “Ingenious solution to low temperature sterilization challenges” • “Has better lumen penetration and can process multiple flexible endoscopes in a single load” • “Has a larger capacity and provides better daily throughput compared to any other low temperature sterilizer” • “

  32. Slide 32: 3M Worldwide Optreoz Sterilizer Web App

    3M Worldwide Optreoz® Sterilizer Web App 32 Courtesy of 3M.

  33. Slide 33: 3M Marketing and Sales Collateral

    3M Marketing and Sales Collateral 33 Courtesy of 3M.

  34. Slide 34: Positioning in Exhibits

    Positioning in Exhibits 34 Courtesy of 3M.

  35. Slide 35: Customer Feedback

    Customer Feedback • “Improving our standard of care by terminally sterilizing devices previously reprocessed using a liquid chemical sterilization method” • “Virtually eliminated the use of the liquid process, as flexible scopes are now terminally sterilized, along with additional devices” • “Runnin

  36. Slide 36: Preparing to Ramp

    Preparing to Ramp 36

  37. Slide 37: Market Potential

    Market Potential 37

  38. Slide 38: Revenues on Unit Sale over 10-year

    Revenues on Unit Sale over 10-year End-User Price $ 640k $480k $320k Margins $160k 1 2 3 4 5 6 7 8 9 10 Year 38

  39. Slide 39: Next Product: STERIZONE 80L Sterilizer

    Next Product • STERIZONE® 80L Sterilizer • Market : OR Sub-Sterile Area • Inventory limitations, flexibility in schedule, shorter turn-around time • Potential placements (NA): > 7,500 units • 50% of customers surveyed want the product Features • Multiple devices in same load • Mix of lumened and sur

  40. Slide 40: STERIZONE 80L Sterilizer

    STERIZONE® 80L Sterilizer 40

  41. Slide 41: Looking Towards the Future

    Looking Towards the Future 41

  42. Slide 42: Our Positioning

    Our Positioning English Francais +86, Creating the improved Standard = in Heatthcare Sterilization Reprocessing™ News & Events About Contact Careers —— | TE, cement Why levest? TOS:TSX « 17.89 +0.40 (+219%) he! ee Investment Strategy cooncateepoany VEDCASt and — Performance reporting to keep imestor

  43. Slide 43: Our Strengths

    Our Strengths • Rapid research & prototyping – Small and flexible structure – Tunable technology • Sterilization testing expertise – Microbiology – Materials compatibility testing • Positive regulatory track record • Licensing-out 43

  44. Slide 44: Strategy

    Strategy • Obtain required regulatory clearances – United States (Optreoz™ 125-Z) – Global (80L) • Increase portfolio – New development – Acquisitions – Joint ventures • Maintain focus on current space – Medical sterile reprocessing 44

  45. Slide 45: Creating Value

    Creating Value • Our offering – Technology and competency based • Our targets – Medical device manufacturers – Sales channels – Investors • Our tactics – Web based – OEM channel 45

  46. Slide 46: What to Expect in 2012?

    What to Expect in 2012 ? • US Regulatory Agency follow-up/clearance on filing for 3M™ OPTREOZ™ 125-Z Sterilizer • Initiate regulatory filings for clearance to sell new OR product (Q3) • Initial commercial activities on the OR product in cleared countries (Q4) 46

  47. Slide 47: Financial Situation – As of March 31

    Financial Situation – As of March 31 Q1 2012 (000’s) Sales & License Revenues 780 Cash, Cash Equivalents & Temporary Investments 9,856 Inventories 885 Total Assets 16,607 Shareholder’s Equity 13,751 Monthly Burn Rate *692 Shares Outstanding 58,786 Options Outstanding 3,751 *After adjustment to elimi

  48. Slide 48: Investment Highlights

    Investment Highlights Large and growing market Superior technology meets customer needs Strong global channel partner Pursuing new applications and opportunities Financially sound 48

  49. Slide 49: © TSO3 Inc., 2012. All rights reserved.

    © TSO3 Inc., 2012. All rights reserved. No part of this publication may be reproduced or translated in any form or by any means, without the prior written permission of TSO3 Inc. - OZO-TEST® - STERIZONE® are Reg. U.S. Pat. & Tm. Off. TSO3 STERIZONE® Sterilizer U.S. Pat. No. 7,128,872 / 7,582,257 / 7

TSO3 — Investor Presentation (April 2012) on 6ix